[go: up one dir, main page]

DE69928100D1 - MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES) - Google Patents

MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES)

Info

Publication number
DE69928100D1
DE69928100D1 DE69928100T DE69928100T DE69928100D1 DE 69928100 D1 DE69928100 D1 DE 69928100D1 DE 69928100 T DE69928100 T DE 69928100T DE 69928100 T DE69928100 T DE 69928100T DE 69928100 D1 DE69928100 D1 DE 69928100D1
Authority
DE
Germany
Prior art keywords
diseases
compounds
ptpases
protein tyrosine
shp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928100T
Other languages
German (de)
Inventor
Peter Moller
Sune Andersen
Fogh Iversen
Hvilsted Olsen
Sven Branner
Dale Holsworth
Farid Bakir
Milburn Judge
Urban Axe
Kevin Jones
Charles Ripka
Yu Ge
Teruyuki Uyeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Priority claimed from PCT/DK1999/000121 external-priority patent/WO1999046267A1/en
Application granted granted Critical
Publication of DE69928100D1 publication Critical patent/DE69928100D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrodes Of Semiconductors (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Bipolar Transistors (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Control Of El Displays (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP.alpha., LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
DE69928100T 1998-03-12 1999-03-11 MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES) Expired - Lifetime DE69928100D1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK34498 1998-03-12
DK48098 1998-04-03
DKPA199800938 1998-07-15
DKPA199801385 1998-10-28
DKPA199801612 1998-12-07
PCT/DK1999/000121 WO1999046267A1 (en) 1998-03-12 1999-03-11 Modulators of protein tyrosine phosphatases (ptpases)

Publications (1)

Publication Number Publication Date
DE69928100D1 true DE69928100D1 (en) 2005-12-08

Family

ID=27512769

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928100T Expired - Lifetime DE69928100D1 (en) 1998-03-12 1999-03-11 MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES)

Country Status (13)

Country Link
EP (1) EP1080095B1 (en)
JP (1) JP2002506072A (en)
KR (1) KR20010041814A (en)
CN (1) CN1300291A (en)
AT (1) ATE308546T1 (en)
AU (1) AU2713599A (en)
BR (1) BR9908726A (en)
CA (1) CA2323493A1 (en)
DE (1) DE69928100D1 (en)
HU (1) HUP0104984A3 (en)
IL (1) IL138319A0 (en)
NO (1) NO20004527L (en)
PL (1) PL342816A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82827C2 (en) 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
CN101103977A (en) * 2002-06-05 2008-01-16 株式会社医药分子设计研究所 Therapeutic agent for diabetes
TW200410671A (en) * 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
CN1658872B (en) 2002-06-06 2010-09-22 株式会社医药分子设计研究所 anti allergy medicine
CN1658855B (en) 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-Substituted Hydroxyaryl Derivatives
DK1753512T3 (en) * 2004-05-28 2008-11-17 4Sc Ag Tetrahydropyridothiophenes
US7517986B2 (en) * 2004-06-04 2009-04-14 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
CA2569623A1 (en) * 2004-06-11 2005-12-22 Altana Pharma Ag Novel compounds and use of tetrahydropyridothiophenes
PL2489659T3 (en) * 2004-06-24 2018-06-29 Vertex Pharma Modulators of ATP-binding cassette transporters
JP2008529989A (en) * 2005-02-09 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Tetrahydropyridothiophene for the treatment of proliferative diseases such as cancer
US7741488B2 (en) * 2005-02-11 2010-06-22 4Sc Ag Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer
JP4908511B2 (en) * 2005-09-15 2012-04-04 エフ．ホフマン−ラ ロシュ アーゲー 4-Amino-thieno [3,2-c] pyridine-7-carboxylic acid derivative
CN1939922B (en) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
KR102074089B1 (en) * 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 Multicyclic compounds and methods of use thereof
CN102382076B (en) * 2010-09-03 2016-08-17 中国医学科学院药物研究所 Arone and aryl amide compound and preparation method thereof and medicinal usage
CN102838625B (en) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 Tetrahydropyridothiazole compound, its preparation method, pharmaceutical composition containing the compound and use thereof
EP2948147B1 (en) 2013-01-28 2019-03-13 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
CN104788425A (en) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 PTP1B inhibitors containing nicotinamide and piperidine structure, and preparation method and use thereof
CN104725308A (en) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 PTP1B inhibitor containing nicotinic acid amide structure, preparation method and use thereof
CN104725306A (en) * 2015-03-12 2015-06-24 佛山市赛维斯医药科技有限公司 A class of PTP1B inhibitors containing nicotinic acid amide structure, preparation method and use thereof
CN104788424A (en) * 2015-03-12 2015-07-22 佛山市赛维斯医药科技有限公司 PTP1B inhibitors containing nicotinamide and piperidine structure, and preparation method and use thereof
CN104829629B (en) * 2015-03-26 2017-03-15 天津药物研究院有限公司 Thiophane simultaneously [2,3 c] pyridine derivate, Preparation Method And The Use containing sulfoamido
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. CONNECTIONS AND COMPOSITIONS AND USES THEREOF
JP7187437B2 (en) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク Compounds and compositions and uses thereof
MX390141B (en) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Methods of treating schizophrenia
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CN112135827B (en) 2018-02-16 2024-01-12 赛诺维信制药公司 Salts, crystal forms and preparation methods thereof
KR20210139376A (en) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 Salts of isochromanyl compounds, and crystalline forms thereof, methods of preparation, therapeutic uses and pharmaceutical compositions
CN113727984B (en) * 2019-05-21 2024-03-15 浙江海正药业股份有限公司 Macrocyclic derivatives, preparation method and application thereof
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
US11629130B2 (en) * 2020-04-14 2023-04-18 Purdue Research Foundation Lymphoid-specific tyrosine phosphatase (LYP) inhibitors

Also Published As

Publication number Publication date
JP2002506072A (en) 2002-02-26
ATE308546T1 (en) 2005-11-15
CA2323493A1 (en) 1999-09-16
NO20004527D0 (en) 2000-09-11
EP1080095B1 (en) 2005-11-02
HUP0104984A3 (en) 2003-07-28
NO20004527L (en) 2000-11-07
PL342816A1 (en) 2001-07-02
KR20010041814A (en) 2001-05-25
HUP0104984A2 (en) 2002-04-29
BR9908726A (en) 2000-11-21
IL138319A0 (en) 2001-10-31
AU2713599A (en) 1999-09-27
EP1080095A1 (en) 2001-03-07
CN1300291A (en) 2001-06-20

Similar Documents

Publication Publication Date Title
DE69928100D1 (en) MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES)
ATE309250T1 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASE (PTPASES)
BR9911786A (en) Heterocyclic p38 inhibitors
DE60216952D1 (en) BETA CARBOLIN DERIVATIVES AS PTP INHIBITORS
DE60028791D1 (en) MODULATORS OF THE PROTEIN TYROSINE PHOSPHATASE (PTPASES)
ATE415164T1 (en) (20S)-1ALPHA-HYDROXY-2ALPHA-METHYL AND 2BETA-METHYL-19-NOR VITAMIN D3 AND THEIR USE
BRPI0408369A (en) indole derivatives useful for treating disease
SI1054887T1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
BR0209575A (en) Pyrazinones, pyridines and pyrimidines substituted as corticotropin releasing factor binders
CY1109069T1 (en) IMIMAZA PYRIDASIN COMPOUNDS
DE60039752D1 (en) PREPARATION OF TETRAVALENT ANTIBODY
DE69729125D1 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
BR0316350A (en) Diaminotriazoles useful as protein kinase inhibitors
MA27063A1 (en) INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS, INTERMEDIATE PRODUCTS, AND THEIR PREPARATION METHOD
BR9910458A (en) Factors affecting tumor necrosis factor receptor release enzyme activity
DE60322186D1 (en) 1-ARYLSULFONYL-3-SUBSTITUTED INDOL AND INDOLINEDERIVATE USEFUL FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
BR9908215A (en) Derivatives of hydroxamic and carboxylic acids
BR0306838A (en) Non-native peptide, isolated nucleic acid, pharmaceutical composition and kit for the prevention or treatment of crf2r-modulated disease
ATE432278T1 (en) COMPOUNDS FOR TREATING DISEASES
ATE271861T1 (en) USE OF NMDA ANTAGONISTS AND/OR SODIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE69520430D1 (en) META SUBSTITUTED ARYLALKYLAMINE AND THERAPEUTIC AND DIAGNOSTIC USE THEREOF
MX2008011473A (en) THE USE OF NICOTINE, ANALOGUES THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEREOF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORM.
ATE313561T1 (en) VGF POLYPEPTIDES AND METHODS FOR TREATING VGF DISEASES
ATE222901T1 (en) CARBOXYL SUBSTITUTED CHROMEDER DERIVATIVES FOR USE AS BETA 3 ADRENORECEPTOR AGONISTS
FI882072A0 (en) NYA SUBSTITUERADE SILYLALKYLENAMINER.

Legal Events

Date Code Title Description
8332 No legal effect for de